And because VEGF is also a key factor in regulating glioma angiogenesis, the results of anti-VEGF therapy showed improved progression-free survival of relapsed GBM (Robles Irizarry et al. 2012). The gene discussed is VEGFA; the disease is central nervous system cancer.